Paratek Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel antibiotics to address unmet medical needs in infectious diseases. The company has developed innovative tetracycline-derived antibiotics designed to combat antibiotic-resistant bacterial infections, which represent a growing global health threat.
Paratek's lead product, omadacycline (marketed as Nuzyra), is a broad-spectrum antibiotic approved by the FDA for treating community-acquired bacterial pneumonia and acute bacterial skin infections. The company has pursued a strategy of addressing both common infections and biodefense applications, including treatments for potential bioterror agents. Paratek operates in the critical but challenging antibiotic development sector, where companies must balance significant development costs with limited commercial incentives due to antibiotic stewardship practices.
Paratek Pharmaceuticals has received investment from 1 venture capital firm.
Biopharmaceutical company developing novel antibiotics to treat antibiotic-resistant bacterial infections.
Paratek Pharmaceuticals has received investment from GreatPoint Ventures. These venture capital firms and investors provide both capital and strategic support.
Paratek Pharmaceuticals operates in the Biotech sector. Biopharmaceutical company developing novel antibiotics to treat antibiotic-resistant bacterial infections.
